

19 Sep 2022 | News

Quick Listen: Scrip's Five Must-Know Things

by [Ian Haydock](#)

In this week's podcast edition of Five Must-Know Things: a big US approval for BMS; Roche touts its diverse R&D pipeline; Lumakras's mixed Phase III results in lung cancer; Japan controversy over a COVID-19 antiviral; and GSK's vaccine strategy in India.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip's* global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 16 September 2022, including: a big US approval for [Bristol Myers Squibb Company](#); [Roche Holding AG](#) touts its diverse R&D pipeline; Lumakras's mixed Phase III results in lung cancer; Japan controversy over a COVID antiviral; and [GSK plc](#)'s vaccine strategy in India.

This and all our other podcasts are available on the Pharma Intelligence channel on [Apple Podcasts](#), [Google Podcasts](#), [SoundCloud](#), [TuneIn](#) and [Spotify Podcasts](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[BMS Aims To Unseat Otezla In Psoriasis With US FDA-Approved Sotyktu](#)" - Scrip, 9 Sep, 2022.)

(Also see "[Roche Plays Down Reliance On TIGIT And Alzheimer's Drugs For Growth](#)" - Scrip, 12 Sep, 2022.)

(Also see "[Amgen's Lumakras Efficacy Confirmed In Phase III, But Not As Strong As Phase II](#)" - Scrip, 12 Sep, 2022.)

SCRIP

CITELINE COMMERCIAL

(Also see "[Japan Physician Groups' Controversial Push For Xocova Backfires](#)" - Scrip, 8 Sep, 2022.)

(Also see "[GSK Eases Cervarix Out Of India, Eyes On Trajectory Of Synflorix](#)" - Scrip, 12 Sep, 2022.)

[Click here to explore this interactive content online](#) ✨